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Abstract
Objective—Systemic lupus erythematosus (SLE) is characterized by intravascular activation of
the complement system and deposition of complement fragments (C3 and C4) on plasma
membranes of circulating cells, including red blood cells (RBC). The aim of this study was to
address whether this process affects the biophysical properties of RBC.
Methods—Serum and red blood cells were isolated from patients with SLE, and healthy controls.
RBC from healthy O Rh negative individuals were incubated with SLE or control serum. We used
flow cytometry to assess complement fragment deposition on RBC. RBC membrane deformability
was measured using 2D microchannel arrays. Protein phosphorylation levels were quantified by
western blot.
Results—Incubation of healthy donor RBC with sera from patients with SLE but not control sera
led to deposition of C4 fragments on the RBC. Complement decorated RBC exhibited significant
decrease in both membrane deformability and flickering. Sera from SLE patients triggered a
transitory Ca++ influx in RBC that was associated with decreased phosphorylation of β-spectrin,
and increased phosphorylation of band 3, two key proteins of RBC cytoskeleton. Finally, SLE but
not control sera led to the production of nitric oxide (NO) by RBC.
Conclusion—Our data suggest that complement activation in patients with SLE leads to calcium
dependent cytosketeletal changes in RBC that render them less deformable, likely impairing their
flow through capillaries. This phenomenon may negatively impact the delivery of oxygen to the
tissues.
Introduction
During systemic lupus erythematosus (SLE) flares, circulating immune complexes lead to
intravascular complement consumption and deposition of nascent C3 and C4 fragments on
red blood cell (RBC) membranes (1–3). Although this phenomenon is well established, very
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little is known about the effect of complement fragment deposition on RBC physiology in
SLE.
In a recent communication, we showed that deposition of C3 and C4 complement fragments
on RBC in vitro, promoted a significant decrease in RBC membrane deformability (4),
which influences the ability of RBC to change shape in response to external forces (5,6).
When RBC enter the microcirculation where the gas exchange takes place, the cell diameter
changes rapidly from 7.5–8 μm to 4.5–5 μm. The dynamic, energy-dependent link between
cell membrane and skeleton is essential for the ability of RBC to pass rapidly through
capillaries without cell fragmentation and critical for maintenance of adequate tissue
perfusion (7,8).
Based on our previous in vitro findings, we hypothesized that deposition of complement
fragments on circulating RBC in SLE leads to impaired RBC deformability. Herein, we
present evidence for the first time that incubation of RBC from healthy donors with sera
from SLE patients resulted in complement fragment deposition, significant changes in the
phosphorylation status of skeletal proteins, and decrease in RBC membrane deformability.
Moreover, RBC with membrane bound complement produce increased amounts of nitric
oxide (NO), an important mediator of pathophysiologic processes characterizing the immune
system deregulation in SLE.
Patients and Methods
Subjects
Thirty-nine patients who fulfilled the American College of Rheumatology criteria for the
diagnosis of SLE (9) and twelve healthy donors donated 20 mL of blood for our studies (53
unique blood collections from SLE patients and 17 from controls). The serum was collected
in serum-separator tubes and RBC in heparin-lithium tubes. The patients were 95% female
with a mean age of 37.5 (23–59) years old. The controls were all female and had a mean age
of 35 (20–52) years old. 56% of SLE patients and 58% of control were white; 23% of SLE
patients and 25% of control were African American; and 20% of SLE patients and 17% of
controls belonged to other races.
The disease activity was calculated using the SLE disease activity index (SLEDAI) (10).
68% of the patients were taking oral prednisone at a mean dose of 23 (2–60) mg per day.
One patient was on intravenous high dose of methyl prednisone (1000 mg). Other
immunosuppressive medications the patients were on at the time of the study:
hydroxychloroquine (66%); azathioprine (19%); mycophenolate mofetil (30%). One patient
was on intravenous monthly cyclophosphamide, one patient was taking cyclosporine and
three patients were taking weekly methotrexate at the time of the study. Prednisone was held
for at least 12 hours prior to the blood draw. The institutional review board of Beth Israel
Deaconess Medical Center approved the study protocol and informed consents were
obtained from all the study subjects.
Reagents
Antibodies (Abs) were obtained as follows: nonimmune IgG1, (BD Biosciences, San Jose,
CA); anti-C4c mAb (A211, Quidel, San Diego, CA), anti-CR1 mAb 1F11 (a gift of Henry
Marsh, PhD, Celldex Immunotherapeutics, Needham, MA), anti-actin, anti-phospho-serine
mAb (Abcam, Cambridge, MA) secondary antibodies: AlexaFluor-488 goat anti–mouse
IgG, AlexaFluor-594 goat anti–rabbit IgG, and AlexaFluor-594 goat anti–mouse IgG
(Invitrogen, Carlsbad, CA); horseradishperoxidase (HRP)-goat anti–mouse IgG, and HRP-
donkey anti–rabbit IgG (Jackson ImmunoResearch, West Grove, PA). Reagents were
obtained as follows: Hank’s Buffer Saline Solution (HBSS) (Invitrogen), protease inhibitor
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cocktail (Roche, Nutley, NJ); IgG-free BSA (Jackson ImmunoResearch). DAF-FM
diacetate, Fluo-4 AM, and eosin 5 maleimide were purchased from Invitrogen.
RBC preparation and deposition of complement fragments
Blood was drawn from healthy adult volunteers in accordance with the guidelines of the
Institutional Review Committee of Beth Israel Deaconess Medical Center and after informed
consent was obtained in accordance with the Declaration of Helsinki. RBC from healthy
universal donors (O Rh negative) were obtained by finger prick (~50μl), resuspended in
1mL of HBSS with Ca++ and Mg++ (HBSS++) (Invitrogen), and washed twice before use.
RBC were then resuspended in HBSS++ with 0.5% IgG-free bovine serum albumin (BSA)
(Jackson ImmunoResearch, West Grove, PA) at a hematocrit of 20%. RBC were incubated
with 20% serum from either SLE patients or normal donors (matched for sex, age and race
to the SLE patient) for 15 minutes at 37°C, and then washed twice and resuspended in
HBSS++.
Serum depletion of C4
One mL of control or SLE sera were incubated with 100 μl of protein A-Sepharose beads
(Pierce, Rockford IL) coupled to either IgG control or anti-C4 mAb for 30 minutes at 4°C.
To prevent complement activation due to immobilized IgG, EDTA was added to the sera to
a final concentration of 5 mM for 10 minutes prior to immune depletion. At the completion
of the reaction, Sepharose beads were removed by centrifugation and initial sera
concentrations of Ca++ (1.5 mM) and Mg++ (1 mM) were restored.
Immunofluorescence microscopy
RBC isolated from healthy universal donors were incubated for 30 minutes at 37°C with
20% sera from healthy control or SLE patients diluted in HBSS with Ca++ and Mg++
(HBSS++). Cells were then washed twice and incubated with 10 μg/mL anti-C4c mAb for
10 minutes in HBSS++ with 0.5% BSA (staining buffer), washed, and stained with
AlexaFluor-594 goat anti–mouse Ab for an additional 15 minutes. After staining, cells were
washed twice, mounted in fluorescence mounting media (DakoCytomation, Carpinteria,
CA), and imaged using an Olympus B×62 fitted with a cooled Hamamatsu Orca AG camera.
The microscope, filters, and camera were controlled by iVision v. 4.0.9 (Biovision
Technologies, Exton, PA).
Measurements of RBC membrane flickering
Phase contrast, time-lapse images of RBC seeded on microscope slides were recorded for 10
seconds representing 250 frames using a 100× UPlanApo phase contrast objective on an
Olympus B×62 microscope (Olympus, Center Valley, PA). Changes in intensity due to
oscillation of RBC membranes (flickering) were measured using iVision v. 4.0.9. At the end
of each recording, an intensity projection step of the image stack was included to identify
and exclude RBC that drifted during recording.
Flow cytometry
Fresh or serum-exposed RBC were incubated for 15 minutes withAb (as noted in the figure
legends) in staining buffer at 4°C, followed by two washes and incubation for 15 minutes
with AlexaFluor–488 labeled secondary Ab specific for each primary Ab at a dilution
recommended by the manufacturer. After incubation with secondary Ab, RBC were washed
once and analyzed using a LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ). In
all experiments, at least 10,000 events were recorded and analyzed (FlowJo, v. 9.0.1,
TreeStar, Ashland, OR).
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Eosin-5-maleimide (EMA) labeling: RBC were incubated with 25% control or SLE sera for
30 minutes at 37°C. RBC were washed and incubated in the presence of HBSS++ with EMA
at a final concentration of 0.1 mg/ml for 20 minutes in the dark at room temperature. RBC
were then washed four times with 1000 μl of HBSS with Ca++ and Mg++ and analyzed by
flow cytometry as described above.
Analysis of RBC calcium influx
RBC (~108) were preloaded with Fluo-4 AM for 15 minutes at room temperature, washed,
and resuspended in HBSS with Ca++ and Mg++. RBC were allow to sit at room temperature
for an additional 10 minutes and washed again to remove any uncleaved Fluo-4 AM. Due to
the ATP-depleting effect of the acetoxymethyl group, all experiments were performed
within one hour from Fluo-4 AM loading of RBC. Fluorescence levels of RBC were
acquired for 15 seconds using a LSRII flow cytometer (BD Biosciences) to establish a
baseline for intra-RBC Ca++ concentration. Fifty μl of control or SLE sera (12.5% of the
final volume) were then added to the RBC, and the fluorescence intensity associated with
intra-RBC Ca++ concentration was recorded for an additional 3 to 5 minutes. Data were
exported as FSC 3.0 files without the time dimension and analyzed using the kinetic module
of FlowJo 9.0.1 (Treestar, Inc.).
Analysis of RBC NO production
RBC were preloaded with DAF-FM diacetate for 30 minutes at room temperature, washed,
and resuspended in HBSS with Ca++ and Mg++. RBC were then analyzed following the
same protocol as described above for Ca++ influx measurements. Certain NO detection
experiments were run for 40 minutes post serum challenge.
Western blot
RBC (3 μL) incubated with normal or SLE serum were lysed in 100 μL of 1× reducing-
loading buffer (Invitrogen) and boiled for 4 minutes. Samples were run on 10% Bis-Tris gels
(Invitrogen), transferred to nitrocellulose paper (Pierce), and blocked with 6% nonfat dry
milk (Biorad, Hercules, CA) in Tris buffer with Tween 0.1% for 1 hour at room temperature.
Membranes were then incubated with Ab as noted in figure legends for 30 minutes at room
temperature, washed, and incubated with HRP-conjugated appropriate secondary Ab for an
additional 30 minutes. Nitrocellulose membranes were washed extensively in Tris buffer
with Tween 0.1% and developed with SuperSignal West Pico Chemiluminescent Substrate
(Pierce) and developed using LAS 4000 imaging system (FujiFilm, Edison, NJ). The
intensity profiles of the protein bands were analyzed using Quantity One v. 4.5.2 (BioRad)
and plotted using GraphPad v. 4.0 (GraphPad Software, Inc. La Jolla, CA)
Fabrication of the 2D filters
To measure the ability of RBC to undergo capillary-like deformations, we fabricated a
pseudo-2D analog of the 5 μm Nuclepore filter comprising an array of posts with 5 μm
openings (channels) between them. The design and fabrication of this microchannel and
configuration of the experimental setup have been described previously in detail (11).
Briefly, we patterned a silicon wafer with an image of the 2D filter in sunken-relief using a
direct laser writer (Heidelberg DWL 66, Heidelberg Instruments Mikrotechnik GmbH,
Heidelberg, Germany) and reactive ion etching (Bosch process, Unaxis SLR 770 ICP Deep
Silicon Etcher, Unaxis USA Inc, St. Petersburg, FL) at the Cornell NanoScale Science &
Technology Facility (Cornell University, Ithaca, NY. Immediately following assembly, the
devices were filled with 1% solution of IgG-free BSA (Jackson ImmunoResearch
Laboratories) in PBS buffer containing 0.01% sodium azide. We found that devices
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fabricated this way can be stored at 4°C and at 100% humidity for at least 6 weeks without
any measurable loss of functionality.
Measuring RBC deformability by 2D filters
To establish the flow of RBC through the 2D filter device the outlet of the 2D filter device
was connected to a waste reservoir (60 mL syringe) (BD Biosciences) with a 60 cm long
piece of PE-60 tubing (Instech Laboratories Inc, Plymouth Meeting, PA) filled with
HBSS++. The difference in level of liquid in the inlet of the 2D filter device and the level of
liquid in the waste reservoir provided the driving pressure difference. The zero pressure
difference corresponded to the absence of movement of RBC within the device. RBC (8 μl,
20% hematocrit) were loaded into the inlet reservoir and allow to enter the network (~ 1
minute) by lowering the waste reservoir tubing. Once RBC entered the capillary area, the
waste reservoir tubing was reconnected to the waste reservoir at a height that allowed RBC
to pass through the 25 μm length of the capillary in about 3 seconds. The passage of RBC
through the 2D network was recorded using a 40×0.75 Ph2 Plan Fluorite objective on a
TE300 Nikon inverted microscope, using a Retiga Exi (QImaging, Canada) CCD camera
controlled by iVision (Biovision) at a rate of 10 frames/second. The time-stacks files were
analyzed frame by frame and the results expressed as seconds necessary for a RBC to pass
through a microchannel.
Results
Sera from SLE patients deposit C4d complement fragments on normal RBC
In order to evaluate the effect of complement deposition on RBC functions, we incubated
normal RBC from universal donors (O Rh negative) with sera from 4 healthy controls or 10
SLE patients. In Figure 1A, we show that incubation of RBC with SLE sera promotes
significant (p=0.016) C4d deposition on RBC membranes in contrast to sera from matched
healthy controls. We then asked whether the deposition of complement fragments on RBC
membranes is due to activation of the classical complement pathway by the immune
complexes present in sera from SLE patients. To answer this question, we repeated the
incubation of RBC from healthy universal donors with sera from control or SLE patients in
the presence or absence of the Ca++ chelator, EGTA. As shown in Figure 1B, lower panel,
removal of Ca++ by 10 mM EGTA inhibited significantly the deposition of C4d on RBC
membranes promoted by SLE serum. Thus, our results suggest that activation of the
classical complement pathway by either immune complexes present in SLE sera or anti-
RBC Abs is responsible for the deposition of C4d on RBC membranes. To discriminate
between these two mechanisms, we incubated RBC with sera from SLE patients and
measured the levels of IgG and IgM on their membranes. Our results show that SLE sera did
not promote significant IgG deposition on RBC membranes (Figure 1A supplemental),
whereas two out of the five SLE sera tested led to IgM deposition on RBC membranes
(Figure 1B supplemental). We concluded, therefore, that the observed deposition of C4d on
RBC membranes is likely due to activation in solution of complement by circulating
immune complexes (12, 13), followed by passive deposition of C4d on by-standing RBC
(14). In certain cases, it is possible that non-hemolytic, complement fixing, anti-RBC IgM
antibodies in SLE patients (15) deposit complement fragments directly on the surface of
RBC. Finally, although in SLE complement is primarily activated through the classical
pathway, the lectin pathway may also contribute to the generation of C4 fragments.
SLE serum decreases RBC membrane deformability
Since deposition of C3 and C4 fragments on RBC membranes leads to significant decrease
in membrane deformability (4), we asked whether SLE serum-dependent deposition of C4d
on normal RBC membranes would induce a similar decrease in membrane deformability.
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RBC from universal donors were exposed to control or SLE sera from patients with mild to
moderate disease activity. We then evaluated RBC membrane deformability by using a
microfluidic device (11,16) (Figure 2A, top panel) and measuring the time necessary for
RBC to pass through a microchannel. As a positive control for complement-mediated
decreased RBC membrane deformability, we deposited complement fragments on RBC
membranes by activating the alternative complement pathway using cobra venom factor and
C7-deficient serum, as previously described (Figure 2B) (4). Our results (Figure 2C and
summary graph 2D) show that incubation with SLE sera significantly delayed the passage
time of RBC through the microchannels when compared to incubation with control sera
(tsle= 26.56 +/−20.83 s, vs. tc=12.65 +/−4.35 s p<0.001). It has to be noted that there was
significant heterogeneity in the effect of SLE serum on individual RBC. In addition, there
was no clear correlation between patient’s disease activity score or specific disease
manifestations and the extent of loss of RBC membrane deformability induced by SLE
serum.
Next, we asked whether circulating RBC from SLE patients also displayed the same
phenotype. We analyzed 3 patients with active SLE (as defined by SLEDAI>4), 2 patients
with inactive disease (SLEDAI<4) and 9 healthy controls. All patients with active disease
showed significant decrease in membrane deformability expressed as increased passage time
(17.86s +/− 3.01) when compared to normal control (10.11s +/− 1.59) or patients with
inactive disease (11.325s +/− 0.46, p=0.001).
Complement deposition inhibits RBC membrane flickering
Besides membrane deformability, the ability of RBC to pass through capillaries is also
impacted by RBC membrane flickering (17), a continuous oscillation of the RBC
membranes at amplitudes varying between 20–400 nm and at frequencies between 0.2–20
Hz (18). We analyzed RBC membrane flickering by measuring changes in light scattering at
the surface of RBC using time-lapse phase contrast microscopy, at a frame rate of 20
frames/second, as previously described (19). RBC from universal donors were incubated
with sera from control (n=2) or SLE patients (n=3) and the extent of C4d deposition on RBC
membrane was quantified before time-lapse recording of membrane flickering by
fluorescence microscopy. As shown in Figure 3, we found an inverse correlation between
the amount of C4d deposition on RBC membranes and the amplitude of membrane
flickering. Changes in flickering amplitude were expressed as standard deviation (SD) of
flickering values. The decrease in flickering amplitude of SLE sera-treated RBC (n=40
analyzed RBC) varied between 10–80% compared to the amplitude of normal serum treated
RBC (n=35 analyzed RBC). Cells that showed an almost complete inhibition of membrane
flickering (Figure 3C) represented about 5% of the total RBC population (Fig. 3D, summary
graph). Most of the RBC displayed intermediate C4d staining (Figure 3B) that resulted in
inhibition of flickering amplitude between 10–45%. Our results suggest that besides
affecting the deformability of RBC membranes, SLE serum-induced complement deposition
is associated with significant decrease in RBC membrane flickering.
SLE serum promotes RBC Ca++ influx and changes in phosphorylation levels of β-spectrin
and band 3
RBC membrane deformability depends on the Ca++-dependent phosphorylation status of
cytoskeletal proteins such as β-spectrin and band 3 (20–22). We therefore asked whether
serum from SLE patients induces a Ca++ influx in RBC that would initiate the events
responsible for the observed decrease in RBC membrane deformability. RBC from healthy
universal donors were preloaded with Fluo-4 AM for 15 minutes, washed, and incubated
with sera from either healthy control or SLE patients, and changes in the intra-RBC Ca++
levels were recorded by time-lapse flow cytometry. In Figure 4A and 4B, we show that sera
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from SLE patients, not from healthy controls, triggered a sustained (over 30 minutes) RBC
Ca++ influx.
RBC cytoskeleton is comprised of elongated α- and β-spectrin tetramers associated with
short actin filaments and accessory proteins that form a dense elastic network on the
cytoplasmic side of plasma membrane (reviewed in (23)). Decrease in serine
phosphorylation levels of β-spectrin was shown to correlate positively with reduced RBC
membrane deformability (20). Therefore, based on our finding regarding the effect of SLE
serum on RBC membrane deformability, we hypothesized that SLE serum promotes de-
phosphorylation of β-spectrin. RBC from healthy universal donors were incubated with
control or SLE sera, lysed and phosphorylation levels of β-spectrin were measured by
western blot using anti-phospho-serine mAb. Our results (Figure 4C and D) show that
compared to sera from healthy donors, sera from SLE patients decreased serine
phosphorylation levels of β-spectrin, thus providing a mechanistic explanation for the
decreased membrane deformability induced by SLE sera and measured by 2D microchannel
array (Figure 2).
Conversely, decreased RBC membrane deformability was recently shown to be associated
with increased levels of band 3 tyrosine phosphorylation (24). Therefore, we tested the
effect of SLE sera on the tyrosine phosphorylation levels of RBC band 3 by flow cytometry
using eosin 5 maleimide (EMA). The binding of EMA to lysine 430 on the extracellular
loop of band 3 parallels tyrosine phosphorylation levels of band 3 through a mechanism that
is currently poorly understood (24). In accordance with deformability data and β-spectrin
phosphorylation results, incubation of RBC from normal universal donors with SLE sera
(n=23) significantly increased (p=0.035) the tyrosine phosphorylation of RBC band 3
compared to healthy control serum (n=7) (Figure 4E and cumulative 4F).
To further prove that the effect of SLE serum on RBC membranes is due to complement
deposition, we depleted the serum of an SLE patient of C4 by immuno-depletion and
measured its biological efficacy in inducing band 3 phosphorylation. Our results show that
depletion of SLE sera of C4 (Figure 5A) resulted in a diminished deposition of C4 fragments
on RBC membrane compared to the original SLE sera and modest phosphorylation of band
3 (Figure 5B).
Overall, these results suggest that SLE serum induced decrease in RBC deformability is
mediated by altered Ca++ dependent phosphorylation of cytoskeletal proteins.
SLE serum induces the production of nitric oxide by RBC
RBC express functional endothelial nitric oxide synthase (eNOS, NOS3), which allows them
to generate biologically active nitric oxide (NO) (25). RBC eNOS is activated by shear
stress-generated Ca++ influx, L-arginine, and phosphorylation via PI3K (26,27). We
therefore hypothesized that Ca++ influx triggered by sera from SLE patients would increase
RBC production of NO. RBC from normal universal donors were preloaded with DAF-FM
diacetate and incubated with sera from healthy control or SLE patients. Our results (Figure
6A and 6B) show that sera from SLE patients promoted a significant increase (p= 0.028) in
intra-RBC production (MFI= 151.4+/−47.53) of NO when compared to sera from healthy
individuals (MFI=104.8 +/−4.42), suggesting that in SLE, complement-decorated RBC
could represent a significant source of intravascular NO.
In conclusion, we present evidence for the first time that in SLE, complement fragment
deposition on RBC membrane alters the phosphorylation pattern of spectrin and band 3,
decreases membrane deformability and flickering, and promotes RBC production of NO.
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Discussion
SLE is characterized by ongoing activation of complement followed by deposition of
complement fragments on circulating RBC (28). Here we present evidence that ex vivo
deposition of C4d on RBC significantly decreases RBC membrane deformability and
flickering, thus negatively impacting the ability of RBC to flow through capillary-like
microchannels. The underlying mechanism for this phenomenon is SLE serum induced Ca++
influx that changes the phosphorylation status of the key cytoskeletal proteins β-spectrin and
band 3. In addition, SLE serum incubated RBC generate NO in significant amounts.
The complete range of functional repercussions of the observed alterations in RBC
deformability by SLE serum remains to be determined. Diminished RBC membrane
deformability may result in decreased ability of RBC to deliver O2 in certain tissues with
narrow capillaries (4–6μm in diameter) such as the brain and muscle (29,30). Our
observation that SLE RBC have decreased membrane deformability may explain, together
with chronic anemia, some of the constitutional symptoms of patients with SLE such as
chronic fatigue (31) and cognitive dysfunction (32,33).
Another important observation in this study is that complement decorated RBC produce
significant amounts of NO. RBC-generated NO has been recently recognized as a key
signaling molecule, directly affecting vascular endothelial cells and smooth muscle cells
during physiological conditions. (34). Moreover, NO was also identified as a significant
factor in promoting signaling abnormalities in SLE T cells, and inducing mitochondrial
proliferation and hyperpolarization (35,36). Mechanistically, extracellular NO and its
derivatives, such as peroxynitrate, have been directly implicated in the pathogenesis of SLE
by modifying the functions of key enzymes and altering the immunogenicity of self-antigens
(reviewed in (37)). Thus, our findings regarding complement-induced RBC NO production
strongly suggest that RBC may play a significant role in SLE pathophysiology.
In conclusion, we describe herein the effect of SLE serum on RBC membrane deformability
and NO production. The altered RBC functional properties that we described could explain
several of the systemic and local manifestations of SLE. Therefore, RBC may not only
prove to be a good SLE biomarker but also an important therapeutic target for intercepting
abnormal signaling events that characterize SLE immunopathology.
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Figure 1.
SLE sera promote C4d deposition on RBC membranes. RBC from healthy individual blood
group O Rh negative were incubated with sera from healthy volunteers or SLE patients. The
expression of C4d on the surface of RBC was measured with flow cytometry and expressed
as mean fluorescent intensity (MFI). A) Cumulative results of C4d deposition on RBC
incubated with sera from healthy individuals (n=7) or SLE patients (n= 27). B) Healthy
control RBC were incubated with SLE serum in the presence (top) or absence (bottom) of
EGTA. A representative (out of three) experiment is shown here.
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Figure 2.
SLE sera decrease RBC membrane deformability. A) Serial snapshots of an RBC passing
through a 2D filter. B) RBC were incubated with C7-depleted serum and cobra venom factor
in the presence (control RBC) or absence (complement-decorated RBC) of EGTA. The RBC
deformability was then analyzed using 2D filters (see Methods). C) RBC from a healthy
universal donor were incubated with sera from healthy individuals (N1, 2), or SLE patients
(L1, 2, 3). RBC deformability was measured using 2D filters. Each dot represents one RBC.
D) Cumulative results from 4 control and 10 SLE sera.
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Figure 3.
Sera from SLE patients inhibit RBC membrane flickering. RBC from a healthy universal
donor were incubated with serum from SLE patients and stained for C4d deposition as
described in Methods. The membrane flickering of RBC displaying no C4d deposition (A,
inset), moderate C4d deposition (B, inset) and high C4d deposition (C, inset) is shown here.
These are representative results of three independent experiments. D) Cumulative results
from 35 RBC incubated with sera from 2 controls and 40 RBC incubated with sera from 3
SLE patients.
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Figure 4.
Sera from SLE patients trigger Ca++ influx and change the phosphorylation profile of β-
spectrin and band 3 in RBC from healthy donors. A) RBC from a healthy universal donor
were preloaded with Fluo-4 AM and incubated with serum from control (N), or SLE patients
(L 2,5) and RBC Ca++ influx measured by flow cytometry. B) Summary graph showing the
Ca++ influx triggered by SLE serum displayed as percent over control. The mean value of
the fluorescence intensity associated with Ca++ concentration over the entire recording was
used as representative fluorescence for each sample. C) SLE serum induces de-
phosphorylation of β-spectrin. RBC from a healthy universal donor were incubated with
serum from a healthy control (N), or SLE patients (L 1–6) for 15 minutes at 37°C, lysed and
the phosphorylation levels of β-spectrin detected using anti-phospho serin/threonin mAb.
Lower panel represents actin loading control of RBC samples. D) Ratio between
phosphorylated β-spectrin and actin levels. E) SLE serum induces phosphorylation of band
3. Band 3 phosphorylation in RBC was measured after staining RBC with EMA as described
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in Methods. RBC incubated with normal serum (N2, filled light grey histogram), or SLE
sera (L1, L2, open histograms) were stained with EMA and analyzed by flow cytometry.
Autofluorescence of unlabeled RBC is shown as filled dark grey histogram. F) Cumulative
results of band 3 phosphorylation in RBC incubated with control (n=7) or SLE (n=23) sera.
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Figure 5.
Depletion of C4 from SLE serum prevents increase in RBC band 3 phosphorylation. SLE
serum was incubated with either IgG control (control serum) or anti-C4c mAb coupled to
Sepharose beads (C4-depleted serum) in the absence of Ca++ and Mg++ for 30 minutes.
RBC were then incubated with either the control (continuous histogram) or the C4-depleted
serum (dotted histogram) and the RBC expression levels of C4d (A) and band 3
phosphorylation (B) were measured by flow cytometry as described above.
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Figure 6.
SLE serum induces the production of nitric oxide (NO) by RBC. A) RBC preloaded with
DAF-FM were incubated with serum from normal individuals (N2) or SLE patients (L1, 3)
for 15 minutes at 37°C. The fluorescence due to normal serum is shown as light gray
histogram. RBC autofluorescence is shown as dark grey histogram. N stands for normal
control and L for SLE patient serum. B) Cumulative data of RBC NO production generated
with sera from 4 controls and 8 SLE patients displayed as percent over control.
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